Study where Diamyd® is administered directly into lymph nodes approved for expansion and inclusion of children from 12 years of age

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that DIAGNODE-1, an open-label clinical pilot study in which the diabetes vaccine Diamyd® is administered directly into lymph nodes, has been approved by the Swedish Medical Products Agency and the Ethics Review Board to be expanded from five to nine patients and to include children from 12 years of age.As previously communicated, Professor Johnny Ludvigsson, principal investigator and sponsor of DIAGNODE-1, has submitted a first preliminary evaluation of data from the first four patients that have been monitored